Individualising patient care is the goal of the Oxford ECMC. This means applying fundamental scientific discoveries in cancer biology to the development of novel cancer therapies and prognostic / diagnostic biomarkers. The Centre focuses on Early Phase trials, and works closely with a number of national and international collaborators from academia and industry.
The Centre is hosted by the University of Oxford, ranked top in the world for medicine, and forms part of its Medical Sciences Division, one of the largest biomedical research centres in Europe. The Centre also benefits from being able to work in partnership with a world-leading centre dedicated to radiation oncology and biology.
The Centre has expertise in immunology, angiogenesis and molecular pathology, and also has facilities for conducting imaging, proteomics, microarray and radioisotope studies.
The specific aims of the Oxford ECMC are to:
Accelerate the development of new cancer treatments, with a specific focus on angiogenesis, DNA damage processing, and immunotherapy
Deliver programmes of concurrent clinical and biomarker research
Stratify patients to ensure that radiotherapy, chemotherapy, immunotherapy and anti-angiogenic treatments are offered to patients in whom these therapies are most likely to work
Our patient population
An audit in 2018/2019 revealed we had around 200 phase I referrals over 12 months of which around 50% entered early phase trials.
Organisations affiliated with the Oxford ECMC:
Oxfordshire – we have both trains and planes (Oxford airport and 60 min from Heathrow)
Contact the Centre Manager: